New Strong Buy Stocks [TOP]
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage. cnx.cmd.push(function() var videoId = decodeURIComponent(""); cnx( playerId: "0a52d238-33b5-4c04-ba5e-323e192cfbe8", mediaId: videoId).render("b8b49474e42e4a61905a1353db504ac9"); );Many investors, especially more aggressive traders, look at lower-priced stocks as a way not only to make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.Skeptics of low-priced shares should remember that at one point Amazon, Apple and Netflix traded in the single digits. One stock we featured over the years, Zynga, was purchased by Take-Two Interactive. Cogent Biosciences, which we featured last March, has tripled since then.We screened our 24/7 Wall St. research database looking for smaller cap companies that could offer patient investors some huge returns for the new year and beyond. While these five stocks are rated Buy and have a ton of Wall Street coverage, it is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.
new strong buy stocks
Conns, Inc. CONN is a specialty retailer of home appliances like refrigerators, freezers, washers, dryers and ranges; consumer electronics like projection, plasma and LCD televisions, camcorders, VCRs, DVD players and home theater products; and home office equipment, lawn and garden products and bedding. It currently operates retail locations in Texas and Louisiana.
Abercrombie & Fitch Company ANF is a specialty retailer of premium, high-quality casual apparel for men, women, and kids through a network of approximately 850 stores across North America, Europe, Asia and the Middle East.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The upgrade of NGL Energy Partners LP to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
The S&P 500 started off 2023 on a strong note after a brutal 2022. However, the labor market remains tight and the Federal Reserve is still raising interest rates in its ongoing battle against inflation. The higher interest rates rise, the more difficult it becomes for S&P 500 companies to grow earnings. In fact, many economists still fear a U.S. recession is just around the corner.
Fortunately, analysts say the unpredictable macroeconomic environment has created a handful of fresh investment opportunities in the market. Here are nine recently upgraded stocks to buy, according to CFRA.
Hasbro is a global toy and entertainment company and is the owner of popular brands such as Peppa Pig, My Little Pony and Magic: The Gathering. Analyst Zachary Warring upgraded Hasbro and says the company's long-term vision and best-in-class execution will create value for investors. Warring is bullish on Hasbro's acquisition of Entertainment One and says Hasbro's entertainment division will be a growth driver for the company and help boost consumer product sales. He says parents will continue to spend on their kids even in a weak economy. CFRA has a "strong buy" rating and $90 price target for HAS stock.
Arch Capital is a Bermuda-based global insurance and reinsurance company. Analyst Catherine Seifert upgraded the stock following the company's fourth-quarter earnings report, which exceeded her expectations in terms of both revenue growth and earnings. Siefert says Arch's stock is undervalued relative to both its property-casualty insurance peers and to its own historical levels. She says Arch's opportunistic approach to underwriting typically yields results that are superior to competitors. Finally, Arch's recent addition to the S&P 500 will increase its visibility among both analysts and investors. CFRA has a "strong buy" rating and $80 price target for ACGL stock.
In contrast to companies in other sectors, the gains and losses in even the best biotech stocks hinge less on earnings results, and more on a few key indicators such as trial-data readouts or verdicts from regulatory agencies. Product approvals unlock vital revenues, so a single positive update can function as a catalyst that propels shares to new highs.
Wall Street pros rightly advise a cautious approach when evaluating the biotechnology industries. We find that monitoring the analyst community can be helpful on a couple fronts: For one, we can see where the pros are putting their faith. Also, analysts can provide much-needed insight into many stocks that get little media coverage, and whose progress can be difficult to gauge unless you're a medical expert.
GW Pharmaceuticals is among the rare biotech stocks with a unanimous Strong Buy rating over the past three months, racking up 12 Buys and 0 Holds or Sells. Ahmad's price target of $224, which is among the highest on GWPH, implies the biotech stock could double by this point in 2021. You can learn more about the analyst community's views on GWPH via TipRanks' consensus breakdown (opens in new tab).
Aptose nearly tripled last year and was one of the best biotech stocks in 2019's late innings. Most of its 197% run came in December after the company released encouraging pre-clinical data on candidate CG-806, including a couple of results that compared favorably to AbbVie's (ABBV (opens in new tab)) Imbruvica: For one, it was more effective in inducing apoptosis (cell death) of CLL cells, and it "demonstrated superior anti-lymphoma effects" in cells of mantle cell lymphoma (MCL). Investors also were encouraged by Merck's (MRK (opens in new tab)) $2.7 billion acquisition of ArQule, whose lead candidate is a treatment type similar to CG-806. 041b061a72